Skip to main content
SpringerLink
Log in

Erlotinib in Advanced Pancreatic Cancer

  • Guest Commentary
  • Published:
American Journal of Cancer

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group [abstract no. 77]. 2005 Gastrointestinal Cancers Symposium; 2005 Jan 27–9; IIollywood (FL)

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, San Francisco Comprehensive Cancer Center, University of California, San Francisco, California, USA

    Andrew H. Ko

Authors
  1. Andrew H. Ko
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ko, A.H. Erlotinib in Advanced Pancreatic Cancer. Am J Cancer 5, 41 (2006). https://doi.org/10.2165/00024669-200605010-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00024669-200605010-00006

Keywords

Search

Navigation